Clinical effects of natalizumab on multiple sclerosis appear early in treatment course

In clinical practice natalizumab is typically used in patients who have experienced breakthrough disease during treatment with interferon beta (IFNβ) or glatiramer acetate. In these patients it is important to reduce disease activity as quickly as possible. In a phase II study, differences between n...

Descripción completa

Detalles Bibliográficos
Autores principales: Kappos, Ludwig, O’Connor, Paul W., Polman, Christopher H., Vermersch, Patrick, Wiendl, Heinz, Pace, Amy, Zhang, Annie, Hotermans, Christophe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2013
Materias:
Original Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3642366/
https://www.ncbi.nlm.nih.gov/pubmed/23292204
http://dx.doi.org/10.1007/s00415-012-6809-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3642366/
https://www.ncbi.nlm.nih.gov/pubmed/23292204
http://dx.doi.org/10.1007/s00415-012-6809-7

Ejemplares similares